Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China · Delayed Price · Currency is CNY 70.60
+1.06 (1.52%)
At close: Jan 23, 2026
Hangzhou Alltest Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Net Income | 294.76 | 302.47 | 180.58 | 1,185 | 765.69 | 679.23 | Upgrade |
Depreciation & Amortization | 32.33 | 32.33 | 39.63 | 58 | 15.59 | 4.03 | Upgrade |
Other Amortization | 10.28 | 10.28 | 10.13 | 6.95 | 2.13 | 1.34 | Upgrade |
Loss (Gain) From Sale of Assets | -1.22 | -1.22 | 0.44 | -0.53 | 0.06 | - | Upgrade |
Asset Writedown & Restructuring Costs | 0.01 | 0.01 | -0.6 | 74.72 | 0.02 | 0.04 | Upgrade |
Loss (Gain) From Sale of Investments | -57.09 | -57.09 | -57.25 | -33.49 | -28.28 | -5.19 | Upgrade |
Provision & Write-off of Bad Debts | 7.87 | 7.87 | 11.33 | 7.82 | 4.08 | 4.51 | Upgrade |
Other Operating Activities | -52.93 | 16.61 | 5.12 | 202.81 | 11.46 | 2.67 | Upgrade |
Change in Accounts Receivable | -52.12 | -52.12 | -14.05 | 129.53 | -124.24 | -90.37 | Upgrade |
Change in Inventory | 19.26 | 19.26 | 12.4 | -13.2 | -264.05 | -71.85 | Upgrade |
Change in Accounts Payable | 28.91 | 28.91 | -199.9 | -221.75 | 537.97 | 100.47 | Upgrade |
Change in Other Net Operating Assets | 14.23 | 14.23 | 20.69 | 11.45 | - | - | Upgrade |
Operating Cash Flow | 252.26 | 329.52 | 24.76 | 1,361 | 923.87 | 622.72 | Upgrade |
Operating Cash Flow Growth | -16.05% | 1230.66% | -98.18% | 47.28% | 48.36% | 580.32% | Upgrade |
Capital Expenditures | -201.93 | -220.65 | -533.49 | -270.24 | -140.12 | -37.11 | Upgrade |
Sale of Property, Plant & Equipment | 5.29 | 1.69 | 0.29 | 0.02 | 0.02 | - | Upgrade |
Cash Acquisitions | - | - | - | -16.61 | - | - | Upgrade |
Investment in Securities | -77.19 | -267.07 | 363.81 | -1,001 | -398.2 | -353 | Upgrade |
Other Investing Activities | 25.89 | 6.97 | 28.72 | 24.01 | 6.95 | 5.19 | Upgrade |
Investing Cash Flow | -247.94 | -479.06 | -140.67 | -1,264 | -531.35 | -384.92 | Upgrade |
Long-Term Debt Repaid | - | -5.66 | -16.39 | -115.56 | -12.65 | - | Upgrade |
Net Debt Issued (Repaid) | -5.66 | -5.66 | -16.39 | -115.56 | -12.65 | - | Upgrade |
Issuance of Common Stock | 8.57 | 8.57 | 8.74 | - | 1,680 | - | Upgrade |
Repurchase of Common Stock | -36.93 | -36.93 | -22.64 | -34.44 | - | - | Upgrade |
Common Dividends Paid | -233.17 | -232.66 | -528.7 | -215.62 | -107.81 | - | Upgrade |
Other Financing Activities | 41.75 | -6.05 | 0.2 | 3.7 | -39.37 | -6.75 | Upgrade |
Financing Cash Flow | -225.44 | -272.73 | -558.79 | -361.91 | 1,520 | -6.75 | Upgrade |
Foreign Exchange Rate Adjustments | 5.92 | 5.98 | 9.48 | 67.86 | -18.72 | -8.43 | Upgrade |
Net Cash Flow | -215.2 | -416.29 | -665.22 | -197.36 | 1,894 | 222.61 | Upgrade |
Free Cash Flow | 50.33 | 108.87 | -508.73 | 1,090 | 783.75 | 585.61 | Upgrade |
Free Cash Flow Growth | -4.65% | - | - | 39.13% | 33.84% | 666.06% | Upgrade |
Free Cash Flow Margin | 5.71% | 12.56% | -67.41% | 32.18% | 41.84% | 51.57% | Upgrade |
Free Cash Flow Per Share | 0.64 | 1.38 | -6.42 | 13.76 | 10.48 | 9.80 | Upgrade |
Cash Income Tax Paid | 11.59 | 8.11 | 15.37 | 85.85 | 65.73 | 50.44 | Upgrade |
Levered Free Cash Flow | -49.02 | 10.23 | -647.33 | 792.39 | 532.31 | 399.02 | Upgrade |
Unlevered Free Cash Flow | -48.85 | 10.49 | -646.42 | 793.75 | 532.72 | 399.02 | Upgrade |
Change in Working Capital | 18.26 | 18.26 | -164.61 | -140.52 | 153.12 | -63.91 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.